Quality-Adjusted Life Years Assessment Using Cabozantinib For Patients With Advanced Hepatocellular Carcinoma (Ahcc) In The Celestial Trial.

JOURNAL OF CLINICAL ONCOLOGY(2019)

Cited 25|Views35
No score
Abstract
207Background: In patients previously treated for aHCC, cabozantinib (cabo) led to longer overall survival and progression-free survival vs placebo (pbo) in the randomized, phase 3 CELESTIAL trial (NCT01908426; N = 707). CELESTIAL was stopped early for benefit at the second interim analysis. This post hoc analysis estimated the incremental quality-adjusted life years (QALYs) accrued in CELESTIAL. Methods: Health utility was elicited at each study visit using the EQ-5D-5L quality of life questionnaire. (completed by 82–100% of patients overall). UK crosswalk tariffs were applied for health states. Cumulative QALYs by patient were calculated by linear interpolation; for patients who were censored (31% of patients; including 9% within 100 days of randomization), the last observed utility value was carried forward to study end. The difference in restricted mean QALYs was calculated using generalized linear models, accounting for baseline utility, and with 0.06–0.08 QALYs considered the minimal important diffe...
More
Translated text
Key words
advanced hepatocellular carcinoma,hepatocellular carcinoma,cabozantinib,life years assessment,quality-adjusted
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined